Presentation is loading. Please wait.

Presentation is loading. Please wait.

Effect of MI-773 dosing on long-term efficacy.

Published byGerald Small Modified over 5 years ago

Similar presentations

Presentation on theme: "Effect of MI-773 dosing on long-term efficacy."— Presentation transcript:

1 Effect of MI-773 dosing on long-term efficacy.
Effect of MI-773 dosing on long-term efficacy. UM-PDX-HACC-5 tumors were transplanted in immunodeficient mice. When tumors reached 200 mm3, animals were randomly allocated into five different treatment regimens as follows: 5 mg/kg saline (vehicle control), 200 mg/kg MI-773 (weekly), 5 mg/kg cisplatin, weekly doses of MI-773 (200 mg/kg) combined with 5 mg/kg cisplatin, or daily doses of MI-773 (28.5 mg/kg) combined with 5 mg/kg cisplatin. A, Graph depicting tumor volume during treatment (tx) and follow-up (43 days) periods. Weekly regimens of MI-773 combined with cisplatin reduced tumors in size and prevented tumor regrowth compared with the other experimental groups or vehicle control. B, Graph depicting mouse weight during the experimental period. Data were normalized against pretreatment weight. C, Graph depicting a linear regression model using repeated measures for each tumor over time. Weekly regimens of MI-773 combined with cisplatin significantly decrease the tumor growth rate when compared with daily regimens of MI cisplatin or single-drug groups (P < 0.001). D, Kaplan–Meier analysis was done using a 2-fold increase in the tumor volume as a criterion for failure as compared with pretreatment volume. MI-773, cisplatin, or daily MI-773 combined with cisplatin extended time to failure significantly as compared with vehicle control (P < 0.05). Graph is depicting the statistical difference between daily and weekly regimens of MI-773 in combination with cisplatin (P = ). E, Graph depicting the volume of each individual xenograft tumor at the 10th posttreatment day. Different lowercase letters (a, b, and c) indicate statistical difference (P < 0.05). F, Western blot analysis for p53, MDM2, p21, BAX, PUMA, and Bcl-2 in UM-PDX-HACC-5 tumors treated with either MI-773 or cisplatin as single agents, weekly or daily regimens of MI-773 combined with cisplatin, or vehicle control. Tumors were harvested 43 days after the last administration of drugs. Felipe Nör et al. Clin Cancer Res 2017;23: ©2017 by American Association for Cancer Research

Download ppt "Effect of MI-773 dosing on long-term efficacy."

Similar presentations

Antitumor effect of the combination of IL-2 IC and anti–CTLA-4.

Antitumor effect of the combination of IL-2 IC and anti–CTLA-4.
A, Effect of folate-FITC (500 nmol/kg, 5 days/week) and/or sunitinib (20 mg/kg daily) therapy on the growth of M109 tumors in Balb/c mice. A, Effect of.

A, Effect of folate-FITC (500 nmol/kg, 5 days/week) and/or sunitinib (20 mg/kg daily) therapy on the growth of M109 tumors in Balb/c mice. A, Effect of.
SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.
Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.
S55746 synergizes with panobinostat in vitro and in vivo in DLBCL

S55746 synergizes with panobinostat in vitro and in vivo in DLBCL
18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition.

18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition.
A B MCF7-ERaWT MCF7-ERaY537S MCF7-ERaY537N MCF7-ERaY537C MCF7-ERaD538G

A B MCF7-ERaWT MCF7-ERaY537S MCF7-ERaY537N MCF7-ERaY537C MCF7-ERaD538G
Effects of AG-221 treatment on survival and cell differentiation in an IDH2R140Q primary human AML xenograft model. Effects of AG-221 treatment on survival.

Effects of AG-221 treatment on survival and cell differentiation in an IDH2R140Q primary human AML xenograft model. Effects of AG-221 treatment on survival.
Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.
Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.

Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.
Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.
Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.
Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.

Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.
Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.

Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.
Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S63845. Improved tumor response.

Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.
A, left: indicated MEFs were transfected as described in the Methods section. A, left: indicated MEFs were transfected as described in the Methods section.

A, left: indicated MEFs were transfected as described in the Methods section. A, left: indicated MEFs were transfected as described in the Methods section.
In vivo efficacy of Olaparib in PTEN deficient xenografts.

In vivo efficacy of Olaparib in PTEN deficient xenografts.
CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.
Treatment with MI-773 causes changes in p53 status.

Treatment with MI-773 causes changes in p53 status.
MI-773 reduces the fraction of CSCs and prevents recurrence in ACC xenograft tumors. MI-773 reduces the fraction of CSCs and prevents recurrence in ACC.

MI-773 reduces the fraction of CSCs and prevents recurrence in ACC xenograft tumors. MI-773 reduces the fraction of CSCs and prevents recurrence in ACC.

Similar presentations

Ads by Google